Group 1 - The company is holding its first extraordinary general meeting of shareholders in 2025 on June 25, 2025, at 14:00, in Shanghai [4][6] - The meeting will be conducted in a combination of on-site and online voting methods, ensuring participation from shareholders [4][6] - The agenda includes the election of a new independent director to replace the outgoing independent director, with a nomination for Mr. Su Shiyan [4][5][6] Group 2 - Shareholders must present valid identification to participate in the meeting and are required to register in advance [2][3] - The meeting will allow shareholders to exercise their rights to speak, inquire, and vote, while maintaining order and respecting the rights of others [2][3] - The company has engaged a lawyer to witness the meeting and provide a legal opinion [4][6] Group 3 - Mr. Su Shiyan, the independent director candidate, has a background in food science and engineering, with extensive experience in the food and beverage industry [6][7] - His qualifications have been reviewed and approved by the Shanghai Stock Exchange, ensuring compliance with regulatory standards [5][6][7] - The company aims to enhance its board's expertise and governance through this appointment [5][6]

证券代码：605388 证券简称：均瑶健康 公告编号：2025-036 湖北均瑶大健康饮品股份有限公司（以下简称"公司"）股票于 2025 年 6 月 11 日、6 月 12 日、6 月 13 日连续 3 个交易日内收盘价格跌幅偏离值累计超 过 20%。根据《上海证券交易所交易规则》的有关规定，属于股票交易异常波动 情形。 经公司自查及向公司控股股东、实际控制人发函核实、确认，截至本公 告披露日，除公司已披露事项外，不存在其它应披露而未披露的重大事项。 请广大投资者理性投资，注意股票二级市场的交易风险。 一、股票交易异常波动的具体情况 公司股票于 2025 年 6 月 11 日、6 月 12 日、6 月 13 日连续 3 个交易日内收 盘价格跌幅偏离值累计超过 20%。根据《上海证券交易所交易规则》的有关规定， 属于股票交易异常波动情形。 二、公司关注并核实的相关情况 （一）生产经营情况 湖北均瑶大健康饮品股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任 重要内容提示： （四）其他股价敏感信息 ...

Group 1 - The core point of the article highlights that Junyao Health plans to distribute a cash dividend of 0.80 yuan per 10 shares despite reporting a revenue decline of 10.77% and a net loss of 29.12 million yuan, marking the first loss in a decade [1][2] - The total cash dividend to be distributed amounts to 46.87 million yuan, which exceeds the dividend amounts during the previous two profitable years [1] - Approximately 67% of Junyao Health's shares are controlled by the founding family, indicating that around 31.52 million yuan of the dividend will benefit them directly [1] Group 2 - Junyao Health's stock price has seen a significant increase, rising from 6.35 yuan on May 23 to a peak of 12.34 yuan by June 10, nearly doubling in just two weeks [1] - This surge in stock price lacks substantial fundamental support, as the company's core product "Weidongli" has shown weak growth, and new ventures in probiotics have not yet reversed the overall decline [2] - Concerns have arisen regarding potential market speculation due to the lack of clear performance indicators supporting the stock price increase [2] Group 3 - Earlier this year, company executives announced share reductions, raising concerns about the company's future prospects [3] - Junyao Health received a warning from the Hubei Securities Regulatory Bureau for failing to disclose its expected annual loss in a timely manner, leading to criticism from the Shanghai Stock Exchange [3] - The chairman's defense regarding his non-involvement in financial data and disclosure processes highlights potential governance issues within the company [3]

Core Viewpoint - The legal opinion letter confirms that Hubei Junyao Health Beverage Co., Ltd.'s differentiated dividend distribution plan for 2024 is compliant with relevant laws and regulations, ensuring no harm to the interests of the company and its shareholders [1][5]. Group 1: Differentiated Dividend Application - The company plans to distribute cash dividends of 0.80 yuan per 10 shares (including tax), totaling 46,865,920 yuan (including tax) to shareholders, excluding shares repurchased [3][4]. - The company has completed the repurchase of 14,660,000 shares, which will not participate in the profit distribution [4]. Group 2: Calculation Basis for Differentiated Dividend - The total share capital of the company is 600,484,000 shares, with 585,824,000 shares participating in the distribution after excluding repurchased shares [4]. - The reference price for ex-dividend is calculated as 7.61 yuan per share based on the closing price of 7.69 yuan per share before the dividend distribution [4][5]. Group 3: Compliance and Impact - The impact of the differentiated dividend on the ex-dividend reference price is less than 1%, indicating minimal effect on the stock price due to the repurchased shares not participating in the dividend [5]. - The legal opinion concludes that the differentiated dividend distribution adheres to the Company Law, Securities Law, and other relevant regulations, ensuring the protection of shareholder interests [5].

证券代码：605388 证券简称：均瑶健康 公告编号：2025-035 湖北均瑶大健康饮品股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 每股分配比例 A 股每股现金红利0.08元 ? 相关日期 | 股份类别 | 股权登记日 | | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/19 | － | 2025/6/20 | 2025/6/20 | | ? 差异化分红送转： 是 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 23 日的2024年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 （1）截至本公告披露日，公司总股本 600,484,000 股，扣除回购专户的股份数 14,660,000 股，本次实际参与分配的 ...

国浩律师（上海）事务所 关 于 湖北均瑶大健康饮品股份有限公司 差异化分红事项 之 专项法律意见书 上海市静安区山西北路 99 号苏河湾中心 MT 25-28 层 邮编：200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai, China 国浩律师（上海）事务所 专项法律意见书 专项法律意见书 电话/Tel: +86 21 52341668 传真/Fax: +86 21 52341670 国浩律师（上海）事务所 网址/Website: http://www.grandall.com.cn 关于湖北均瑶大健康饮品股份有限公司 2025 年 6 月 差异化分红事项之 致湖北均瑶大健康饮品股份有限公司： 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）、《上市公司股份回购规则》（以 下简称"《回购规则》"）、《上海证券交易所上市公司自律监管指引第 7 号— —回购股份》（以下简称"《监管指引第 7 号》"）、《上海证券交易所股票上 市规则》（以下简称"《上市 ...

证券代码：605388 证券简称：均瑶健康 公告编号：2025-035 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 湖北均瑶大健康饮品股份有限公司 2024年年度权益分派实施公告 A 股每股现金红利0.08元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/19 | － | 2025/6/20 | 2025/6/20 | 差异化分红送转： 是 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 23 日的2024年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 差异化分红送转方案： （1）截至本公告披露日，公司总股本 600,484,000 股，扣除回购专户的股份数 14,660,0 ...

证券代码：605388 证券简称：均瑶健康 公告编号：2025-034 湖北均瑶大健康饮品股份有限公司 关于召开 2025 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 6 月 17 日（星期二）上午 10:00-11:00 会议召开方式：网络文字互动 投资者可于 6 月 16 日（星期一）16:00 前登录上证路演中心网站首页点 击"提问预征集"栏目或通过公司邮箱 juneyaodairy@juneyao.com 进行提问。公 司将在说明会上对投资者普遍关注的问题进行回答。 湖北均瑶大健康饮品股份有限公司（以下简称"公司"）已于 2025 年 4 月 30 日发布《公司 2025 年第一季度报告》，为便于广大投资者更全面深入地了解 公司 2025 年第一季度经营成果、财务状况，公司计划于 2025 年 6 月 17 日上午 10:00-11:00 举行 2025 年第一季度业绩说明会，就投资者关心的问题进行交流， 在信息披露允许的范围内就投资者普遍关注 ...

Core Viewpoint - Junyao Health, known as the "first stock of lactic acid bacteria drinks," received a warning letter for failing to timely disclose its performance loss announcement, marking its first loss since going public in 2020 [2][5][10]. Financial Performance - In 2024, Junyao Health reported revenue of 1.458 billion yuan, a year-on-year decline of 10.77%, and a net profit loss of 29.12 million yuan, a year-on-year drop of 150.57% [7][10]. - The loss was primarily attributed to impairment provisions for goodwill (36.43 million yuan), inventory write-downs (12.76 million yuan), and credit impairment losses (36.60 million yuan) [8]. Stock Market Reaction - Despite the poor financial performance, Junyao Health's stock price surged, closing at 12.05 yuan per share on the first trading day after receiving the warning letter, marking a 10.05% increase and a new high for the year [2][13]. - Analysts suggest that the regulatory penalty has removed uncertainty, contributing to the stock's recovery, although there may be emotional or artificial factors influencing the price movements [6][13]. Executive Actions - During the stock price surge, several executives, including directors and supervisors, engaged in concentrated share sell-offs, totaling 383,400 shares and approximately 3.5373 million yuan in cash [4][15]. - The shareholding structure shows significant pledging, with the largest shareholder, Junyao Group, pledging about 151 million shares, accounting for 76.69% of its holdings and 25.11% of the total share capital [19][20].

证券代码：605388 证券简称：均瑶健康 公告编号：2025-034 湖北均瑶大健康饮品股份有限公司 关于召开 2025 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 6 月 17 日（星期二）上午 10:00-11:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com） 会议召开方式：网络文字互动 投资者可于 6 月 16 日（星期一）16:00 前登录上证路演中心网站首页点 击"提问预征集"栏目或通过公司邮箱 juneyaodairy@juneyao.com 进行提问。公 司将在说明会上对投资者普遍关注的问题进行回答。 湖北均瑶大健康饮品股份有限公司（以下简称"公司"）已于 2025 年 4 月 30 日发布《公司 2025 年第一季度报告》，为便于广大投资者更全面深入地了解 公司 2025 年第一季度经营成果、财务状况，公司计划于 2025 年 ...